Core Insights - 2026 is identified as a pivotal year for Denali, particularly with the anticipated approval of tividenofusp alfa for Hunter syndrome [8] Company Overview - Denali is in the final stages of seeking approval for its first product, tividenofusp alfa, which targets Hunter syndrome [8]